Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research note

Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and 2020

Anju Murayama1, 2, *, Kenji Nakano2, Sae Kamamoto1, 3, Masaya Sato1, 4, Hiroaki Saito1, 5, Tetsuya Tanimoto1, 6, Akihiko Ozaki1, 7

1) Medical Governance Research Institute, Minato-ku, Tokyo, Japan
2) Tohoku University School of Medicine, Sendai City, Miyagi, Japan
3) Hamamatsu University School of Medicine, Hamamatsu City, Shizuoka, Japan
4) School of Engineering, Hokkaido University, Sapporo City, Hokkaido, Japan
5) Department of Internal Medicine, Soma Central Hospital, Soma City, Fukushima, Japan
6) Department of Internal Medicine, Navitas Clinic Tachikawa, Tachikawa, Tokyo, Japan
7) Department of Breast and Thyroid Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki City, Fukushima, Japan

article info

Article history:
Received 24 April 2022
Received in revised form
17 July 2022
Accepted 23 July 2022
Available online 5 August 2022

Editor: A. Kalil

Keywords:
COVID-19
Health policy
Industry payments
Infectious disease physician
Open payments
Physician payment
Physician payments sunshine act
SARS-CoV-2
United States

abstract

Objective: To evaluate the trend in nonresearch payments made by the industries to the infectious disease physicians in the United States since the launch of the Open Payments Database and during the COVID-19 pandemic.

Methods: Descriptive analysis was performed for the nonresearch payments made to all infectious disease physicians listed in the Open Payments Database between 2014 and 2020. Using the generalized estimating equation models with panel data of monthly and yearly payment per physician, the payment trend since the inception of the Open Payments Database and during the early stage of the COVID-19 pandemic were evaluated.

Results: A total of 7901 (81.5%) infectious disease physicians received $156 837 987 in nonresearch payments between 2014 and 2020. Median annual payments were $197 to $220. Monthly nonresearch per-physician payments and number of physicians with payments rapidly decreased by 58.6% (95% CI: 49.7%–65.9%, p < 0.001) and by 54.4% (95% CI: 52.7%–56.1%, p < 0.001) at the beginning of the COVID-19 pandemic, respectively. However, the per-physician payments and number of physicians with payments slightly increased every month right after onset of the pandemic. Both per-physician payments and the number of physicians with payments decreased by 2.6% (95% CI: 0.45%–4.7%, p = 0.018) and 2.0% (95% CI: 0.6%–2.4%, p < 0.001) since the inception of the Open Payments Database, respectively.

Discussion: The nonresearch payments and number of infectious disease physicians accepting payments had decreased since the inception of the Open Payments Database. Furthermore, the non-research payments to infectious disease physicians suddenly decreased by more than half due to the COVID-19 pandemic. Anju Murayama, Clin Microbiol Infect 2022;28:1655.e1–1655.e4

© 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Introduction

In response to the increasing social demand for transparency in financial relationships between healthcare professionals and industry, the Open Payments Database, a legal-binding database of payments made by nearly all pharmaceutical companies and device companies, has launched since 2013 in the United States [1]. This transparency initiative put pressure on physicians accepting payments from industries and led to the decline in the number of physicians receiving payments across specialties [2]. Furthermore, the rapid COVID-19 pandemic would have been estimated to have restricted the physician behaviours as well as promotional activities by the healthcare industries. However, no study has assessed the financial relationships between the U.S. infectious disease physicians

* Corresponding author. Anju Murayama, Medical Governance Research Institute, Minato-ku, Tokyo, 1087505, Japan.
E-mail address: ange21tera@gmail.com (A. Murayama).

https://doi.org/10.1016/j.cmi.2022.07.023
1198-743X/© 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
and the industries during early stage of the COVID-19 pandemic as well as since the launch of the Open Payments Database.

**Methods**

This study examined the trend in the nonresearch payments made to the infectious disease physicians by the industries during early stage of the COVID-19 pandemic and since the launch of the Open Payments Database. All general (nonresearch) payments made to physicians whose primary specialty was categorized as “Infectious Disease” or “Pediatric Infectious Diseases” in the Open Payments profile database were extracted from January 2014 to December 2020. Descriptive analyses of the annual payments were performed. Trend in payments before and after the COVID-19 pandemic were evaluated by the interrupted time series (ITS) analysis using generalized estimating equation models of monthly payments per physician, as in previous studies [3,4]. The national emergency concerning the COVID-19 pandemic was declared in the U.S. on March 13, 2020, we considered March 2020 as the onset of the COVID-19 pandemic and the period before and after March 2020 as before the COVID-19 pandemic and after the COVID-19 pandemic for the analysis of monthly trend, respectively. To stabilize the seasonality of payment patterns, we included month as a categorical variable in the monthly ITS model. As a sensitivity analysis, we also evaluated the yearly trend using the same generalized estimating equation models with individual yearly payment data. The proportion of infectious disease physicians receiving payments were calculated based on number of active infectious disease physicians reported in the Association of American Medical Colleges’ Physician Specialty Data Report each year. The Gini index was used to evaluate inequality in payment distribution [4].

**Results**

The Open Payments Database included 7901 (equal to 81.5% of all active infectious disease physicians in the U.S. in 2019) infectious disease physicians receiving a total of $156,837,987 general payments between 2014 and 2020. Monthly general payments per physician and the number of physicians with payments substantially decreased by 58.6% (95% CI: 49.7%–65.9%, p < 0.001) and by 54.4% (95% CI: 52.7%–56.1%, p < 0.001) at the onset of the COVID-19 pandemic (Fig. 1 and Supplemental Table 1). However, the payments and the number of physicians with payments slightly increased every month after the pandemic (Fig. 1). The payments per physician significantly decreased among the physicians with lower payments since the inception of the Open Payments Database (Supplemental Table 1). The payment trends by payment categories were described in Supplemental Figure 1. Although the payments for travel and food/beverage significantly decreased, there was fewer decrease or no change in consulting, education payments, and speaking compensations during the pandemic.

For the yearly analyses, the total annual payments decreased from $24,831,760 in 2019 to $13,418,203 in 2020 (Table 1). The annual payments per physician and annual number of physicians with payments decreased by 37.6% (95% CI: 28.5%–45.6%, p < 0.001) and 21.2% (95% CI: 19.3%–23.1%, p < 0.001) in 2020, the year of the COVID-19 pandemic, compared to those between 2014 and 2019, respectively.

For the payment trend between 2014 and 2019, the number of infectious disease physicians receiving payments decreased from 4715 in 2014 to 4279 in 2019, with the average relative yearly change rate of −2.0% (95% CI: −2.4% to −1.6%, p < 0.001). Median payments per physician ranged from $197 (IQR: $59–$859) in 2018 to $220 (IQR: $67–$1038) in 2015, whereas the average ranged from $4,511 (SD: $22,428) in 2018 to $5,605 (SD: $26,656) in 2019. There was a slightly decreasing trend in payments per physician. The Gini coefficient for annual payments per physician was 0.925, indicating that large amounts of nonresearch industry payments significantly concentrated on small number of infectious disease physicians. The top one third physicians received 98.7% ($154,734,828) of overall payments, mainly for speaking compensations ($69,918,633; 45%) and consulting payments ($45,695,571; 30%). Meanwhile, food and beverage payments accounted for more than three quarters of total payments made to middle and bottom one third of physicians (Supplemental Figure 2).

**Discussion**

This study highlighted that the nonresearch payments made to infectious disease physicians by the pharmaceutical and medical
### Table 1

| Variables | Programme year | Average relative yearly change, % |
|-----------|----------------|-----------------------------------|
| Total payments, $ | 2014 | 23 633 270 |
| | 2015 | 26 423 645 |
| | 2016 | 24 282 286 |
| | 2017 | 24 187 800 |
| | 2018 | 20 061 022 |
| | 2019 | 24 831 760 |
| | 2020 | 13 418 203 |
| Number of physicians with payments, n (%) | 2014 | 18 004 (61.8) |
| | 2015 | 19 617 (61.5) |
| | 2016 | 18 928 (61.2) |
| | 2017 | 19 124 (59.8) |
| | 2018 | 19 078 (59.5) |
| | 2019 | 19 057 (58.0) |
| | 2020 | 13 077 (44.2) |
| Payments per physician, $ | 2014 | 10 012 (31.3) |
| | 2015 | 11 250 (32.0) |
| | 2016 | 11 606 (32.5) |
| | 2017 | 12 569 (34.4) |
| | 2018 | 13 084 (34.5) |
| | 2019 | 13 045 (33.7) |
| | 2020 | 10 720 (31.2) |

### Transparency declaration

HS received nonresearch fees from Taiho Pharmaceutical Co. Ltd outside the scope of the submitted work. AO and TT received nonresearch fees from Bionics Co. Ltd, a medical device company, outside the scope of the submitted work. TT also received nonresearch fees from Medical Network Systems, a dispensing pharmacy, outside the scope of the submitted work. Regarding non-financial conflicts of interest, all are engaged in ongoing research examining financial and non-financial conflicts of interest among healthcare professionals and pharmaceutical companies in Japan and the United States. The other authors have no example conflicts of interest to disclose. There was no funding source for this study.
Author contributions

AM was responsible for conceptualization, methodology, software, formal analysis, investigation, resources, data curation, writing the original draft, review and editing, visualisation, and supervision. KN was responsible for methodology, software, investigation, resources, and review and editing. SK was responsible for conceptualization, methodology, software, formal analysis, investigation, resources, and review and editing. MS was responsible for methodology, software, data curation, formal analysis, investigation, resources, and review and editing. HS was responsible for conceptualization, methodology, software, writing the original draft, and review and editing. TT was responsible for conceptualization, methodology, writing the original draft, review and editing, and supervision. AO was responsible for conceptualization, methodology, software, writing the original draft, review and editing, and study administration.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2022.07.023.

References

[1] Pham-Kanter G. Act II of the sunshine act. PLoS Med 2014;11:e1001754.
[2] Marshall DC, Taras ES, Rosenzweig K, Korenstein D, Chimonas S. Trends in industry payments to physicians in the United States from 2014 to 2018. JAMA 2020;324:1785–8.
[3] Kusumi E, Murayama A, Kamamoto S, Kawashima M, Yoshida M, Saito H, et al. Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Blood Cancer J 2022;12:54.
[4] Murayama A, Kamamoto S, Saito H, Yamada K, Bhandari D, Shoji I, et al. Pharmaceutical payments to Japanese board-certified infectious disease specialists: a four-year retrospective analysis of payments from 92 pharmaceutical companies between 2016 and 2019. Int J Environ Res Public Health 2022;19:7417.
[5] Slentz DH, Nelson CC, Lichter PR. Characteristics of industry payments to ophthalmologists in the open payments database. JAMA Ophthalmol 2019;137:1038–44.
[6] Taras ES, Marshall DC, Rosenzweig K, Korenstein D, Chimonas S. Trends in industry payments to medical oncologists in the United States since the inception of the Open Payments Program, 2014 to 2019. JAMA Oncol 2021;7:440–4.
[7] Annapureddy A, Murugiah K, Minges KE, Chui PW, Desai N, Curtis JP. Industry payments to cardiologists. Circ Cardiovasc Qual Outcome. 2018;11:e005016.
[8] Johnson L, Stricker RB. Attorney General forces infectious diseases society of America to redo Lyme guidelines due to flawed development process. J Med Ethics 2009;35:283–8.
[9] Thacker PD. Covid-19: how independent were the US and British vaccine advisory committees? BMJ 2021;373:n1283.
[10] Stein GE, Kamler JJ, Chang JS. Ophthalmology patient perceptions of Open Payments information. JAMA Ophthalmol 2018;136:1375–81.
[11] Mitchell AP, Trivedi N, Gennarelli RL, Chimonas S, Tabatabai SM, Goldberg J, et al. Are financial payments from the pharmaceutical industry associated with physician prescribing?: a systematic review. Ann Intern Med 2021;174:53–61.
[12] Khan R, Nugent CM, Scaffidi MA, Gimpaya N, Grover SC. Association of biologic prescribing for inflammatory bowel disease with industry payments to physicians. JAMA Intern Med 2019;179:1424–5.
[13] Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS. Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts. JAMA Intern Med 2016;176:763–8.